{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:36Z","timestamp":1790916816517,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":153,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101277","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:40:33Z","timestamp":1781257233000},"page":"101277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Brentuximab vedotin in cutaneous T-Cell lymphoma: emerging evidence and therapeutic insights for CD30-negative and CD30-low disease"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9333-1123","authenticated-orcid":false,"given":"Renee","family":"Morecroft","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Phillipps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhamad Alhaj","family":"Moustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.ctarc.2026.101277_bib0001","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1200\/JCO.2000.18.15.2908","article-title":"Primary cutaneous T-cell lymphoma: review and current concepts","volume":"18","author":"Siegel","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101277_bib0002","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.3390\/cancers12102921","article-title":"Epidemiology of cutaneous T-cell lymphomas: a systematic review and meta-analysis of 16,953 patients","volume":"12","author":"Dobos","year":"2020","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101277_bib0003","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/archderm.143.7.854","article-title":"Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002","volume":"143","author":"Criscione","year":"2007","journal-title":"Arch. Dermatol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101277_bib0004","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/bjh.17117","article-title":"The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma","volume":"192","author":"Scarisbrick","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101277_bib0005","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.beha.2018.07.007","article-title":"Integrating novel systemic therapies for the treatment of mycosis fungoides and S\u00e9zary syndrome","volume":"31","author":"Prince","year":"2018","journal-title":"Best Pr. Res. Clin. Haematol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101277_bib0006","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/mabs.20230","volume":"4","author":"Van De Donk","year":"2012","journal-title":"MAbs"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101277_bib0007","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/cup.13894","article-title":"A review of CD30 expression in cutaneous neoplasms","volume":"48","author":"Kampa","year":"2021","journal-title":"J. Cutan. Pathol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101277_bib0008","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1158\/1078-0432.CCR-09-2069","article-title":"Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate","volume":"16","author":"Okeley","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101277_bib0009","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30\u2013monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101277_bib0010","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1535-7163.MCT-23-0118","article-title":"Brentuximab Vedotin-driven microtubule disruption results in endoplasmic reticulum stress leading to immunogenic cell death and antitumor immunity","volume":"23","author":"Heiser","year":"2024","journal-title":"Mol. Cancer Ther."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101277_bib0011","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/oncolo\/oyac137","article-title":"Response to Brentuximab Vedotin by CD30 expression in non-hodgkin lymphoma","volume":"27","author":"Jagadeesh","year":"2022","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101277_bib0012","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1182\/blood.V94.9.3077","article-title":"CD30-CD30 Ligand interaction in primary cutaneous CD30+T-cell lymphomas: a clue to the pathophysiology of clinical regression","volume":"94","author":"Mori","year":"1999","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.ctarc.2026.101277_bib0013","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase II trial of Brentuximab Vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.ctarc.2026.101277_bib0016","first-page":"2243","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician\u2019s choice in cutaneous T-cell lymphoma: final data","volume":"8","author":"Horwitz","year":"2024","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101277_bib0019","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3324\/haematol.2021.278301","article-title":"A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas","volume":"106","author":"Kim","year":"2021","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101277_bib0020","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/bjd.20588","article-title":"Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and s\u00e9zary syndrome with variable CD30 positivity","volume":"185","author":"Papadavid","year":"2021","journal-title":"Br. J. Dermatol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101277_bib0021","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/ijd.13696","article-title":"Brentuximab vedotin in CD30+ primary cutaneous T-cell lymphomas: a review and analysis of existing data","volume":"56","author":"Enos","year":"2017","journal-title":"Int. J. Dermatol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101277_bib0022","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/jdv.18563","article-title":"Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: data from the Spanish primary cutaneous lymphoma registry","volume":"37","author":"Muniesa","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.ctarc.2026.101277_bib0023","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S0959-8049(21)00656-0","article-title":"Response to brentuximab vedotin in advanced stage MF\/S\u00e9zary syndrome with low CD-30 expression: \u201creal-life\u201d data of the German cutaneous lymphoma network","volume":"156","author":"Blazejak","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101277_bib0024","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jamadermatol.2020.4901","article-title":"Brentuximab Vedotin for relapsed or refractory s\u00e9zary syndrome","volume":"157","author":"Lewis","year":"2021","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ctarc.2026.101277_bib0025","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/1535-7163.MCT-25-0062","article-title":"TUB-010, a novel anti-CD30 antibody-drug conjugate based on Tub-tag technology, widens the therapeutic window by reducing toxicity while maintaining high efficacy","volume":"25","author":"Gerlach","year":"2026","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101277_bib0026","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12835","article-title":"Impressive response of CD30-negative, treatment-refractory mycosis fungoides to brentuximab vedotin","volume":"32","author":"Goyal","year":"2019","journal-title":"Dermatol. Ther."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101277_bib0027","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/bjd.17254","article-title":"Dramatic response to brentuximab vedotin in refractory nontransformed CD30\u2013 mycosis fungoides allowing allogeneic stem cell transplant and long-term complete remission","volume":"180","author":"Mah\u00e9vas","year":"2019","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101277_bib0028","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1001\/jamadermatol.2017.3961","article-title":"Treatment of CD30-negative refractory mycosis fungoides with Brentuximab Vedotin","volume":"154","author":"Zhang","year":"2018","journal-title":"JAMA Dermatol."},{"issue":"32","key":"10.1016\/j.ctarc.2026.101277_bib0014","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of Brentuximab Vedotin in mycosis fungoides and s\u00e9zary syndrome with variable CD30 expression level: a Multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101277_bib0018","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ejca.2021.01.054","article-title":"Response to brentuximab vedotin versus physician\u2019s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: an ALCANZA sub-analysis","volume":"148","author":"Kim","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"10094","key":"10.1016\/j.ctarc.2026.101277_bib0015","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101277_bib0029","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1046\/j.1365-2141.1996.d01-1686.x","article-title":"CD30 ligand is expressed on resting normal and malignant human B lymphocytes","volume":"93","author":"Younes","year":"1996","journal-title":"Br. J. Haematol"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101277_bib0030","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers"},{"issue":"10168","key":"10.1016\/j.ctarc.2026.101277_bib0031","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101277_bib0032","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5045\/br.2017.52.4.243","article-title":"Brentuximab vedotin: clinical updates and practical guidance","volume":"52","author":"Yi","year":"2017","journal-title":"Blood Res."},{"key":"10.1016\/j.ctarc.2026.101277_bib0033","unstructured":"DailyMed - ADCETRIS- brentuximab vedotin injection, powder, lyophilized, for solution [Internet]. [cited 2025 Feb 23]. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=3904f8dd-1aef-3490-e48f-bd55f32ed67f#ID_e4bc4929-6c06-bc6a-5cc5-4bc068915dc7."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101277_bib0034","doi-asserted-by":"crossref","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","article-title":"T-cell lymphomas, Version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Horwitz","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.ctarc.2026.101277_bib0035","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Primary Cutaneous Lymphomas. Version 2.2025. National Comprehensive Cancer Network; 2025. Accessed [2025 Feb 8]. Available at: NCCN.org."},{"key":"10.1016\/j.ctarc.2026.101277_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113343","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/s\u00e9zary syndrome \u2013 Update 2023","volume":"195","author":"Latzka","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101277_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2023.10.001","article-title":"Real-world treatment patterns and clinical outcomes with Brentuximab Vedotin or other standard therapies in patients with previously treated cutaneous T-cell lymphoma in the United States","volume":"24","author":"Barta","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101277_bib0038","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1080\/10428194.2023.2216820","article-title":"Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas","volume":"64","author":"Ribereau-Gayon","year":"2023","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101277_bib0039","first-page":"383","article-title":"Combination of brentuximab-vedotin with skin-directed therapies extends the time to the next therapeutic line in patients with cutaneous T-cell lymphoma","volume":"19","author":"Stranzenbach","year":"2021","journal-title":"J. Dtsch Dermatol. Ges."},{"key":"10.1016\/j.ctarc.2026.101277_bib0040","unstructured":"Brentuximab Vedotin in combination with Mogamulizumab in treating patients with stage II-IV sezary syndrome or mycosis fungoides - NCI [Internet]. [cited 2025 Oct 4]. Available from: https:\/\/www.cancer.gov\/research\/participate\/clinical-trials-search\/v?id=NCI-2024-00766."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101277_bib0041","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1021\/acs.bioconjchem.1c00058","article-title":"Innovative bioconjugation technology for antibody-drug conjugates: proof of concept in a CD30-positive lymphoma mouse model","volume":"32","author":"Juen","year":"2021","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ctarc.2026.101277_bib0042","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S0959-8049(21)00656-0","article-title":"Response to brentuximab vedotin in advanced stage MF\/S\u00e9zary syndrome with low CD-30 expression: \u201creal-life\u201d data of the German cutaneous lymphoma network","volume":"156","author":"Blazejak","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101277_bib0043","unstructured":"Phase I trial of SGN-35C, a novel CD30-directed antibody-drug conjugate, in R\/R lymphomas | VJHemOnc [Internet]. [cited 2025 Dec 10]. Available from: https:\/\/www.vjhemonc.com\/video\/ycmosd6dbyw-phase-i-trial-of-sgn-35c-a-novel-cd30-directed-antibody-drug-conjugate-in-rr-lymphomas\/?utm_source=chatgpt.com."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101277_bib0044","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/bloodadvances.2021005714","article-title":"Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models","volume":"6","author":"Wu","year":"2022","journal-title":"Blood Adv."},{"issue":"16","key":"10.1016\/j.ctarc.2026.101277_bib0045","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1158\/1078-0432.CCR-21-0194","article-title":"Phase I, first-in-human study of the Probody therapeutic CX-2029 in adults with advanced solid tumor malignancies","volume":"27","author":"Johnson","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101277_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1225610","article-title":"Novel anti-CD30\/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity","volume":"14","author":"Faber","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.ctarc.2026.101277_bib0047","unstructured":"Study Details | NCT03602157 | Study of CAR-T cells expressing CD30 and CCR4 for r\/r CD30+ HL and CTCL | ClinicalTrials.Gov [Internet]. [cited 2025 Dec 10]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03602157?utm_source=chatgpt.com."},{"key":"10.1016\/j.ctarc.2026.101277_bib0048","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.968395","article-title":"CAR-T cell development for cutaneous T cell lymphoma: current limitations and potential treatment strategies","volume":"13","author":"To","year":"2022","journal-title":"Front Immunol."},{"issue":"23","key":"10.1016\/j.ctarc.2026.101277_bib0017","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician\u2019s choice in cutaneous T-cell lymphoma: final data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.ctarc.2026.101277_bib0049","unstructured":"Brentuximab Vedotin for adult patients with primary cutaneous anaplastic large cell lymphoma - the ASCO post [Internet]. [cited 2025 Oct 4]. Available from: https:\/\/ascopost.com\/issues\/december-25-2017\/brentuximab-vedotin-for-adult-patients-with-primary-cutaneous-anaplastic-large-cell-lymphoma\/."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:58:17Z","timestamp":1790913497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226001887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":49,"alternative-id":["S2468294226001887"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101277","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brentuximab vedotin in cutaneous T-Cell lymphoma: emerging evidence and therapeutic insights for CD30-negative and CD30-low disease","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101277","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101277"}}